172 related articles for article (PubMed ID: 11872273)
1. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer.
Rödel C; Grabenbauer GG; Papadopoulos T; Bigalke M; Günther K; Schick C; Peters A; Sauer R; Rödel F
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):294-303. PubMed ID: 11872273
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation.
Rödel C; Grabenbauer GG; Rödel F; Birkenhake S; Kühn R; Martus P; Zörcher T; Fürsich D; Papadopoulos T; Dunst J; Schrott KM; Sauer R
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1213-21. PubMed ID: 10725634
[TBL] [Abstract][Full Text] [Related]
4. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.
Rödel F; Hoffmann J; Grabenbauer GG; Papadopoulos T; Weiss C; Günther K; Schick C; Sauer R; Rödel C
Strahlenther Onkol; 2002 Aug; 178(8):426-35. PubMed ID: 12240548
[TBL] [Abstract][Full Text] [Related]
5. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Terzi C; Canda AE; Sagol O; Atila K; Sonmez D; Fuzun M; Gorken IB; Oztop I; Obuz F
Int J Colorectal Dis; 2008 Jan; 23(1):37-45. PubMed ID: 17805549
[TBL] [Abstract][Full Text] [Related]
6. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
Sprenger T; Rothe H; Jung K; Christiansen H; Conradi LC; Ghadimi BM; Becker H; Liersch T
World J Surg Oncol; 2010 Apr; 8():27. PubMed ID: 20388220
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
Sauer R; Fietkau R; Wittekind C; Rödel C; Martus P; Hohenberger W; Tschmelitsch J; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R;
Colorectal Dis; 2003 Sep; 5(5):406-15. PubMed ID: 12925071
[TBL] [Abstract][Full Text] [Related]
8. [Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas].
Tannapfel A; Nüsslein S; Katalinic A; Köckerling F; Wittekind C; Fietkau R
Strahlenther Onkol; 1998 Jun; 174(6):295-9. PubMed ID: 9645209
[TBL] [Abstract][Full Text] [Related]
9. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer.
Tannapfel A; Nüsslein S; Fietkau R; Katalinic A; Köckerling F; Wittekind C
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):585-91. PubMed ID: 9635706
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
12. High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Wolff HA; Gaedcke J; Jung K; Hermann RM; Rothe H; Schirmer M; Liersch T; Herrmann MKA; Hennies S; Rave-Fränk M; Hess CF; Christiansen H
Strahlenther Onkol; 2010 Jan; 186(1):30-35. PubMed ID: 20082185
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
14. P27 does not predict histopathological response to radiochemotherapy in rectal cancer.
Günther K; Dimmler A; Rödel F; Reulbach U; Merkel S; Bittorf BR; Matzel KE; Papadopoulos T; Hohenberger W; Sauer R; Rödel C
J Surg Res; 2003 Aug; 113(2):179-88. PubMed ID: 12957127
[TBL] [Abstract][Full Text] [Related]
15. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081
[TBL] [Abstract][Full Text] [Related]
16. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
17. Integration of novel agents into combined-modality treatment for rectal cancer patients.
Rödel C; Sauer R
Strahlenther Onkol; 2007 May; 183(5):227-35. PubMed ID: 17497093
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
20. Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
Pasetto LM; Friso ML; Pucciarelli S; Basso U; Rugge M; Sinigaglia G; Rossi E; Compostella A; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(6B):4129-35. PubMed ID: 19192672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
